Effect of subanesthetic dose of esketamine on anesthetic recovery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000040077

Enrollment

Unknown

Registered

2020-11-20

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anesthetic recovery

Interventions

Group K:0.2mg/Kg esketamine i.v.

Group N:Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Informed consent; 2. Elective laparoscopic cholecystectomy; 3. ASA I-II; 4. aged 18 to 65 years.

Exclusion criteria

Exclusion criteria: 1. Liver or kidney dysfunction; 2. Operation time is greater than 2 hours; 3. Intraoperative changes; 4. BMI>35 or <18kg*m-2; 5. History of neurological disease; 6. Long-term alcoholism; 7. Intraoperative bleeding is greater than 200ml.

Design outcomes

Primary

Measure	Time frame
anesthetic recovery time;	—

Secondary

Measure	Time frame
postoperative pain;	—

Countries

China

Contacts

Public ContactCao Zhang

the Fourth Affiliated Hospital of Zhejiang University School of Medicine

bioger@126.com+86 15858931168

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026